Interferon alfa-n3

PreclinicalSmall molecule

IInterferon Sciences

Interferon alfa-n3 is one of 7 small molecule programs targeting Double-blind. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Double-BlindCompleted

Double-BlindPreclinical

Completed

Competition

Competitive Landscape

10 competitors in Double-Blind

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

1 2

Albenza

IImpax Laboratories, LLC

Phase 3

1 3

Everolimus and Lonafarnib

BBoston Children's Hospital

Phase 3

1 4

Inosine Pranobex

NNewport Pharmaceuticals International

Preclinical

2 5

PORT-77

PPortal Therapeutics, Inc.

Phase 1

1 6

Western Therapy

JJiangxi Qingfeng Pharmaceutical Co. Ltd.

Preclinical

1 7

Interferon alfa-n3

IInterferon Sciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Double-blind3 trials

Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients

Completed·IInterferon Sciences·N/A·NCT00002012·45 enrolled

Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects

Completed·IInterferon Sciences·N/A·NCT00002018·60 enrolled

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000844·560 enrolled

Immunodeficiency1 trial

Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection

Completed·PPurdue Frederick·Phase 1·NCT00002078

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Interferon alfa-n3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Interferon alfa-n3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Interferon alfa-n3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Interferon Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInterferon Sciences

Interferon alfa-n3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Double-blind3 trials

Immunodeficiency1 trial

References

Drug Info

Quick Facts

Related News